Movement Alert｜AstraZeneca PLC Falls 7.22% in Regular Trading, Potential $400 Billion Merger With Bristol-Myers Squibb Sparks Integration Concerns

Market Focus08-03 21:34

On August 3, AstraZeneca PLC fell 7.22% in regular trading, trading at $157.38/share, with turnover of $200 million.

On the news front, AstraZeneca PLC is reportedly in talks with Bristol-Myers Squibb about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, ranking among the largest pharmaceutical mergers ever. The discussions have been ongoing for several months, though a deal could still be delayed or fail to materialize. The transaction would likely be structured as a mix of cash and stock.

AstraZeneca PLC currently has a market capitalization of approximately $264 billion, while Bristol-Myers Squibb is valued at around $133 billion. Bristol-Myers Squibb is preparing for patent expirations on core products Eliquis and Opdivo, which together account for roughly half of its sales. The market is concerned about acquisition premiums and integration risks given heavy overlap in oncology portfolios, with cancer drugs contributing approximately 44% and 50% of each company's revenue respectively. Bristol-Myers Squibb shares rose over 4% in contrast.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149919860?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149919860","market":"us","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca PLC Falls 7.22% in Regular Trading, Potential $400 Billion Merger With Bristol-Myers Squibb Sparks Integration Concerns","media":"Market Focus","content":"<p><p>On August 3, AstraZeneca PLC fell 7.22% in regular trading, trading at $157.38/share, with turnover of $200 million.</p><p>On the news front, AstraZeneca PLC is reportedly in talks with Bristol-Myers Squibb about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, ranking among the largest pharmaceutical mergers ever. The discussions have been ongoing for several months, though a deal could still be delayed or fail to materialize. The transaction would likely be structured as a mix of cash and stock.</p><p>AstraZeneca PLC currently has a market capitalization of approximately $264 billion, while Bristol-Myers Squibb is valued at around $133 billion. Bristol-Myers Squibb is preparing for patent expirations on core products Eliquis and Opdivo, which together account for roughly half of its sales. The market is concerned about acquisition premiums and integration risks given heavy overlap in oncology portfolios, with cancer drugs contributing approximately 44% and 50% of each company's revenue respectively. Bristol-Myers Squibb shares rose over 4% in contrast.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca PLC Falls 7.22% in Regular Trading, Potential $400 Billion Merger With Bristol-Myers Squibb Sparks Integration Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca PLC Falls 7.22% in Regular Trading, Potential $400 Billion Merger With Bristol-Myers Squibb Sparks Integration Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, AstraZeneca PLC fell 7.22% in regular trading, trading at $157.38/share, with turnover of $200 million.</p><p>On the news front, AstraZeneca PLC is reportedly in talks with Bristol-Myers Squibb about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, ranking among the largest pharmaceutical mergers ever. The discussions have been ongoing for several months, though a deal could still be delayed or fail to materialize. The transaction would likely be structured as a mix of cash and stock.</p><p>AstraZeneca PLC currently has a market capitalization of approximately $264 billion, while Bristol-Myers Squibb is valued at around $133 billion. Bristol-Myers Squibb is preparing for patent expirations on core products Eliquis and Opdivo, which together account for roughly half of its sales. The market is concerned about acquisition premiums and integration risks given heavy overlap in oncology portfolios, with cancer drugs contributing approximately 44% and 50% of each company's revenue respectively. Bristol-Myers Squibb shares rose over 4% in contrast.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1149919860","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149919860","pubTimestamp":1785764090,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, AstraZeneca PLC fell 7.22% in regular trading, trading at $157.38/share, with turnover of $200 million.On the news front, AstraZeneca PLC is reportedly in talks with Bristol-Myers Squibb...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"走势警报|阿斯利康公司常规交易下跌 7.22%，与百时美施贵宝潜在 4000 亿美元合并引发整合担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On August 3, AstraZeneca PLC fell 7.22% in regular trading, trading at $157.38/share, with turnover of $200 million.On the news front, AstraZeneca PLC is reportedly in talks with Bristol-Myers Squibb about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, ranking among the largest pharmaceutical mergers ever. The discussions have been ongoing for several months, though a deal could still be delayed or fail to materialize. The transaction would likely be structured as a mix of cash and stock.AstraZeneca PLC currently has a market capitalization of approximately $264 billion, while Bristol-Myers Squibb is valued at around $133 billion. Bristol-Myers Squibb is preparing for patent expirations on core products Eliquis and Opdivo, which together account for roughly half of its sales. The market is concerned about acquisition premiums and integration risks given heavy overlap in oncology portfolios, with cancer drugs contributing approximately 44% and 50% of each company's revenue respectively. Bristol-Myers Squibb shares rose over 4% in contrast.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149919860","isCrawlerRequest":true}